The disease

What is chikungunya and how do you get it?

Chikungunya is a disease caused by infection with chikungunya virus. Mosquitoes become infected when they bite an infected person or non-human primate. The virus replicates in the mosquito, and when the mosquito bites another person, the virus is spread to that person. 

Healthcare and laboratory workers can be infected by handling blood that contains the virus. And, on rare occasions, the virus can spread from a pregnant person to their developing fetus, most commonly during the second trimester. The baby can also be infected during delivery if their mother is infected. The virus has not been found in breast milk. 

Not everyone with chikungunya will have symptoms. Symptoms that do occur, usually start three to seven days after being infected. Common symptoms include: 

• High fever
• Joint pain that can be severe, debilitating, and affect multiple joints (most commonly those in the hands and feet)
• Headache
• Fatigue
• Muscle pain
• Nausea or vomiting
• Rash 

Rare complications can include:

• Inflammation of the eye
• Damage to liver and kidneys
• Swelling of brain or spinal cord
• Guillain-Barré syndrome (GBS)
• Neurologic dysfunctions 

Newborns, people more than 65 years of age and those with underlying health conditions are at greater risk for severe disease. Most people recover within 7 to 10 days. However, joint pain and fatigue can be severe and may last for months or even years. People do not usually die from chikungunya disease. 

The vaccine

Chikungunya vaccine is recommended for some, but not all, travelers. Most travelers can protect themselves by taking steps to avoid mosquito bites, such as using insect repellent that contains DEET, wearing protective clothing, choosing lodging with air conditioning or screens on windows and doors, and using a mosquito net if sleeping outdoors.

People recommended to get a chikungunya vaccine include: 

• Travelers to regions experiencing outbreaks
• People traveling for more than 6 months to places with elevated risk of an outbreak
• Laboratory workers who handle chikungunya virus

If you are not sure if you would be recommended to get a chikungunya vaccine, talk to your healthcare provider or occupational safety team. If you will be traveling, you might consider scheduling an appointment at a travel medicine clinic. (See “Vaccine Considerations for Travelers” webpage.)

One chikungunya vaccine is currently approved for use in the U.S. It is a virus-like particle (VLP) vaccine for people 12 years of age and older as a single dose. (This is a strategy similar to that used to make the human papillomavirus vaccine (HPV)). VLPs are proteins that look like the virus but do not contain the genetic material. Because VLPs do not contain genetic material, they cannot replicate or cause an infection.

How is the chikungunya vaccine made?

The VLP vaccine is made from structural proteins from the virus. Genes that are the blueprint for the proteins are added to a plasmid (a small circular piece of DNA) and that plasmid is placed into human embryonic kidney cells. As the cells reproduce in the lab, they also make the chikungunya virus proteins. The chikungunya proteins are then purified and used as the vaccine (see” How Are Vaccines Made?”).

Does the chikungunya vaccine work?

Clinical trials of the VLP vaccine showed that 98 of 100 people 12 to 64 years of age and 87 of 100 people 65 years of age and older developed an immune response against chikungunya virus by three weeks after vaccination. Eighty-five of 100 people between 12 and 64 years of age and 76 of 100 people 65 years of age and older still had a measurable immune response against chikungunya virus six months after vaccination. Researchers are still collecting data to determine how long immunity lasts beyond six months. 

Does the chikungunya vaccine have side effects?

Common side effects of the chikungunya VLP vaccine include pain at the injection site, fatigue, headache, and muscle aches. Similar concerns related to safety of the VLP vaccine in elderly patients have not been reported as described for the live, weakened chikungunya vaccine, which is currently not available in the U.S.

Other questions you might have

What if I am traveling with a child too young to get chikungunya vaccine?

A chikungunya vaccine is not available for children less than 12 years of age. Until an approved vaccine becomes available for children less than 12, they should be protected from mosquito bites in other ways, such as: 

• Using insect repellent that contains N,N-diethyl-3-methylbensamide, more commonly referred to as DEET (Note: Insect repellent should not be used on children younger than 2 months of age, and for those older than 2 months, the percent of DEET should be as low as possible. Combination sunscreen and insect repellent products should not be used in children either).
• Wear loose-fitting, long-sleeved shirts and pants and closed-toe shoes. Mosquitos may still be able to bite through thin clothing.
• Choose lodging with screens on windows and doors.
• Use mosquito nets for sleeping if screens are not available. 

If anyone in your party develops symptoms, including fever, headache, muscle and joint pain, or a rash, see a healthcare provider immediately and be sure to let them know where you recently traveled. 

Was there a different chikungunya vaccine?

A live, weakened chikungunya vaccine was available between November 2023 and August 2025. It was made by deleting a gene from chikungunya virus that caused it to lose its ability to replicate well in people. The vaccine virus was grown in monkey kidney cells in the lab. Because the vaccine contained a live, weakened virus, it was not recommended to be used in pregnant people or those with weakened immune systems. 

The live, weakened vaccine was recommended as a single dose for people 18 years and older. Clinical trials showed that 99 in 100 people who received it developed an immune response against chikungunya virus by four weeks after vaccination. Three years later, 96 of 100 people still had an immune response against the virus. 

Some people who received the live, weakened vaccine experienced soreness at the injection site, headache, fatigue, myalgia, arthralgia (joint pain), fever and nausea. In some people these side effects could be severe or prolonged (30 days or more). 

The license for the vaccine was revoked in August 2025, after several reports of elderly people requiring hospitalization for cardiac or neurologic events after vaccination.  Many of the patients who experienced severe side effects had underlying health conditions and recovered within a few weeks. According to the FDA’s report, one death was attributed to receipt of the vaccine with high certainty. Because of the potential for severe side effects and because another vaccine was available that did not have the same safety concerns, the live, weakened chikungunya vaccine was removed from use in the U.S.

Relative risks and benefits

Do the benefits of the VLP chikungunya vaccine outweigh the risks?

Chikungunya is not common in the U.S. No cases of chikungunya acquired in the U.S. or its territories have occurred since 2019. But some U.S. travelers may benefit from vaccination based on their travel itinerary. While chikungunya is not deadly, the disease can be debilitating, including causing long-lasting joint pain. 

People who may be exposed to the virus because they work with it in a laboratory setting may also benefit from vaccination.

For these reasons only a limited number of people in the U.S. are recommended to get this vaccine. 

Disease risks

• Fever
• Severe joint pain
• Headache, muscle pain, nausea and vomiting, rash
• Joint pain lasting for months or years
• Rare complications, including inflammation of the eye, damage to liver and kidneys, swelling of brain or spinal cord, Guillain-Barré syndrome (GBS), and neurological symptoms

Vaccine risks

• People 12 to 64 years: Injection site pain, fatigue, headache, muscle pain
• People over 64 years of age: Injection site pain, fatigue, muscle pain 

References

• Orenstein WA, Offit PA, Edwards KM and Plotkin SA. Ebola Vaccines in Plotkin's Vaccines, 8th Edition. 2024, 176.
• Freppel W, Silva LA, Stapleford KA, Herrero LJ. Pathogenicity and virulence of chikungunya virus. Virulence 2024; 15 (1): 2396484

Reviewed by Paul A. Offit, MD, on Nov. 25, 2025